349 related articles for article (PubMed ID: 28799819)
1. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
3. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
5. What have we learnt from the clinical outcomes trials with the cetrapibs?
Doggrell SA
Curr Opin Lipidol; 2018 Aug; 29(4):327-332. PubMed ID: 29630000
[TBL] [Abstract][Full Text] [Related]
6. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE;
N Engl J Med; 2017 May; 376(20):1933-1942. PubMed ID: 28514624
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
9. Future of cholesteryl ester transfer protein inhibitors.
Rader DJ; deGoma EM
Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
Armitage J; Holmes MV; Preiss D
J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
[TBL] [Abstract][Full Text] [Related]
11. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
Eyvazian VA; Frishman WH
Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
[TBL] [Abstract][Full Text] [Related]
12. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Taheri H; Filion KB; Windle SB; Reynier P; Eisenberg MJ
Cardiology; 2020; 145(4):236-250. PubMed ID: 32172237
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?
Doggrell SA
Expert Opin Pharmacother; 2018 Apr; 19(6):611-615. PubMed ID: 29498299
[TBL] [Abstract][Full Text] [Related]
17. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
[TBL] [Abstract][Full Text] [Related]
18. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
19. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
20. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
Menon V; Kumar A; Patel DR; St John J; Riesmeyer J; Weerakkody G; Ruotolo G; Wolski KE; McErlean E; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32179516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
